225 related articles for article (PubMed ID: 37921068)
41. miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
Lv L; Li Q; Chen S; Zhang X; Tao X; Tang X; Wang S; Che G; Yu Y; He L
Exp Cell Res; 2019 Dec; 385(1):111597. PubMed ID: 31525340
[TBL] [Abstract][Full Text] [Related]
42. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach.
Zhang Z; Lu T; Zhang Z; Liu Z; Qian R; Qi R; Zhou F; Li M
Biochem Pharmacol; 2024 Apr; 222():116117. PubMed ID: 38461903
[TBL] [Abstract][Full Text] [Related]
43. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
Lei G; Liu S; Yang X; He C
Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
[TBL] [Abstract][Full Text] [Related]
44. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
45. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.
Lai HH; Lin LJ; Hung LY; Chen PS
Biochem Biophys Res Commun; 2018 Nov; 506(1):87-93. PubMed ID: 30336979
[TBL] [Abstract][Full Text] [Related]
46. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
[TBL] [Abstract][Full Text] [Related]
47. Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.
Li JM; Jiang GM; Zhao L; Yang F; Yuan WQ; Wang H; Luo YQ
Oncol Rep; 2019 Nov; 42(5):1725-1734. PubMed ID: 31436301
[TBL] [Abstract][Full Text] [Related]
48. Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and β1 integrin/FAK-mediated signalling.
Klobučar M; Grbčić P; Pavelić SK; Jonjić N; Visentin S; Sedić M
Biochem Biophys Res Commun; 2018 Sep; 503(2):843-848. PubMed ID: 29920241
[TBL] [Abstract][Full Text] [Related]
49. MIR600HG suppresses metastasis and enhances oxaliplatin chemosensitivity by targeting ALDH1A3 in colorectal cancer.
Yao Y; Li N
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32270866
[TBL] [Abstract][Full Text] [Related]
50. Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells.
Jang CH; Moon N; Oh J; Kim JS
Nutrients; 2019 Apr; 11(4):. PubMed ID: 30987009
[TBL] [Abstract][Full Text] [Related]
51. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity.
Di Y; Jing X; Hu K; Wen X; Ye L; Zhang X; Qin J; Ye J; Lin R; Wang Z; He W
Drug Resist Updat; 2023 Jan; 66():100909. PubMed ID: 36525936
[TBL] [Abstract][Full Text] [Related]
52. Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1.
Rattanawong A; Payon V; Limpanasittikul W; Boonkrai C; Mutirangura A; Wonganan P
Oncol Rep; 2018 Jan; 39(1):227-238. PubMed ID: 29138869
[TBL] [Abstract][Full Text] [Related]
53. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
54. Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer.
Xu Y; Zhu M
Clin Transl Oncol; 2020 Jul; 22(7):1105-1116. PubMed ID: 31728833
[TBL] [Abstract][Full Text] [Related]
55. Butyrate supplementation regulates expression of chromosome segregation 1‑like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
Chang CC; Kao WY; Liu CY; Su HH; Kan YA; Lin PY; Ku WC; Chang KW; Yang RN; Huang CJ
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35417036
[TBL] [Abstract][Full Text] [Related]
56. miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions.
Tsai HL; Miao ZF; Chen YT; Huang CW; Yeh YS; Yang IP; Wang JY
J Cell Mol Med; 2019 May; 23(5):3572-3582. PubMed ID: 30834693
[TBL] [Abstract][Full Text] [Related]
57. Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy.
Arriaga JM; Greco A; Mordoh J; Bianchini M
Mol Cancer Ther; 2014 May; 13(5):1369-81. PubMed ID: 24634414
[TBL] [Abstract][Full Text] [Related]
58. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z
Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039
[TBL] [Abstract][Full Text] [Related]
59. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
60. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]